SLC38A7 and cancer: Previous studies revealed potential of aberrant glutamine metabolism as a target of cancer therapy and diagnosis4, 7–11, 31, and this aberrant metabolism accompanies overexpression of the corresponding amino acid transporters including ASCT26–8 as we also demonstrated in in vitro and in vivo (Fig. 2 and Supplementary Fig. S13).